問卷

TPIDB > Search Result

Search Result

篩選

List

19Cases

2019-10-31 - 2023-10-05

Phase II

Completed
A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
  • Condition/Disease

    Systemic Lupus Erythematosus(SLE)

  • Test Drug

    PF-06700841

Participate Sites
8Sites

Recruiting8Sites

2021-10-29 - 2025-07-07

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting1Sites

Recruiting3Sites

2023-07-01 - 2024-12-17

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2024-07-01 - 2027-01-31

Phase II

Active
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome
  • Condition/Disease

    Sjögren’s Syndrome

  • Test Drug

    injection

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2024-10-01 - 2027-12-31

Phase II

Active
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBEXELIMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
  • Condition/Disease

    SYSTEMIC LUPUS ERYTHEMATOSUS

  • Test Drug

    injection

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2025-09-16 - 2031-12-31

Phase II

Active
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Radiographic Axial Spondyloarthritis (Ankylosing Spondylitis)
  • Condition/Disease

    Radiographic Axial Spondyloarthritis

  • Test Drug

    皮下注射劑

Participate Sites
7Sites

Recruiting7Sites

2018-08-01 - 2025-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2022-02-01 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2023-05-31 - 2027-09-30

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2024-01-15 - 2031-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

1 2